Provided by Tiger Trade Technology Pte. Ltd.

Edgewise Therapeutics, Inc.

30.05
+0.36001.21%
Post-market: 30.050.00000.00%16:20 EDT
Volume:653.60K
Turnover:19.61M
Market Cap:3.22B
PE:-18.43
High:30.34
Open:29.69
Low:29.40
Close:29.69
52wk High:31.82
52wk Low:10.60
Shares:107.27M
Float Shares:60.85M
Volume Ratio:0.81
T/O Rate:1.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6302
EPS(LYR):-1.6302
ROE:-34.19%
ROA:-23.02%
PB:6.17
PE(LYR):-18.43

Loading ...

Edgewise Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
Mar 17

Edgewise Therapeutics Price Target Maintained With a $32.00/Share by Wedbush

Dow Jones
·
Mar 17

U.S. RESEARCH ROUNDUP- Biogen, Eli Lilly, Johnson & Johnson

Reuters
·
Mar 17

Edgewise Therapeutics Inc : JP Morgan Raises Target Price to $45 From $34

THOMSON REUTERS
·
Mar 17

Analysts’ Top Healthcare Picks: Edgewise Therapeutics (EWTX), Sarepta Therapeutics (SRPT)

TIPRANKS
·
Mar 16

Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Integer Holdings (ITGR) and Edgewise Therapeutics (EWTX)

TIPRANKS
·
Mar 11

Edgewise Therapeutics Says Sevasemten Shows Long-Term Functional Stability in Becker Muscular Dystrophy

MT Newswires Live
·
Mar 10

Edgewise’s New EDG-7500 Study Signals Broader Cardiovascular Ambitions

TIPRANKS
·
Mar 07

Wedbush Keeps Their Buy Rating on Edgewise Therapeutics (EWTX)

TIPRANKS
·
Mar 06

Edgewise Therapeutics to Present at Leerink Global Healthcare Conference

Reuters
·
Mar 04

Edgewise Therapeutics to Present Sevasemten Becker Muscular Dystrophy Data at 2026 MDA Clinical and Scientific Conference

Reuters
·
Mar 03

Stock Track | Edgewise Therapeutics Plummets 5.19% Intraday Following Q4 Earnings Miss and Inducement Grants

Stock Track
·
Mar 02

Edgewise Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 02

Edgewise Therapeutics Reports Inducement Stock Option Grants Under Nasdaq Rules

Reuters
·
Mar 02

Edgewise Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

THOMSON REUTERS
·
Mar 02

Edgewise Therapeutics Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Feb 27

RBC Capital Sticks to Its Buy Rating for Edgewise Therapeutics (EWTX)

TIPRANKS
·
Feb 27

Edgewise Therapeutics Q4 EPS $(0.47) Misses $(0.43) Estimate

Benzinga
·
Feb 27

Earnings Flash (EWTX) Edgewise Therapeutics Posts Q4 Net Loss $0.47 a Share, vs. FactSet Est of $0.40 Loss

MT Newswires Live
·
Feb 26

Edgewise Therapeutics posts Q4 net loss of USD 50.2 million, R&D expenses USD 43.6 million (+16.3%)

Reuters
·
Feb 26